TELCON RF PHARMACEUTICAL (200230) Fundamentals 2026 — Revenue Analysis | SniperIQ
TELCON RF PHARMACEUTICAL (200230) is a KR-listed Technology company in Communication Equipment with a market capitalization of ₩14.4B, trading at ₩2020.00 on the KOE. This SniperIQ fundamentals page covers TELCON RF PHARMACEUTICAL's valuation, profitability (net margin -19.4%), revenue (₩43.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TELCON RF PHARMACEUTICAL's market cap?
TELCON RF PHARMACEUTICAL (200230) has a market capitalization of approximately ₩14.4B, trading at ₩2020.00 on the KOE. Market cap moves with the live share price.
What is TELCON RF PHARMACEUTICAL's P/E ratio?
TELCON RF PHARMACEUTICAL's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Technology sector peers rather than read in isolation.
How profitable is TELCON RF PHARMACEUTICAL?
TELCON RF PHARMACEUTICAL runs a net profit margin of -19.4%, a gross margin of 16.2%, and an operating margin of 1.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TELCON RF PHARMACEUTICAL generate?
TELCON RF PHARMACEUTICAL reported revenue of ₩43.2B for fiscal year 2025, with net income of -₩11.5B and earnings per share (EPS) of -1707.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TELCON RF PHARMACEUTICAL pay a dividend?
TELCON RF PHARMACEUTICAL does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is TELCON RF PHARMACEUTICAL financially healthy?
TELCON RF PHARMACEUTICAL carries a debt-to-equity ratio of 0.41x and a current ratio of 1.24x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TELCON RF PHARMACEUTICAL a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TELCON RF PHARMACEUTICAL (200230) the key facts are: market cap ₩14.4B, revenue ₩43.2B, 52-week range 1990-44050. Weigh valuation, profitability, growth, and balance-sheet strength against Technology peers and form your own view.
Track TELCON RF PHARMACEUTICAL's full fundamentals live
Get TELCON RF PHARMACEUTICAL's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.